Navigation Links
Stem cell therapy shows promise in regenerating damaged muscle in heart attack patients

Heart attack patients who received an new intravenous adult stem cell therapy, Provacel? experienced a lower number of adverse events, such as cardiac arrhythmias, and had significant improvements in heart, lung and global function compared to those who received a placebo, according to six-month Phase I study data presented at the American College of Cardiology's Innovation in Intervention: i2Summit in New Orleans on March 25.

Rush was one of 10 premier cardiac centers across the country that participated in the 53-patient, double-blind, placebo-controlled trial. Among other findings, patients receiving Provacel were 75 percent less likely to experience an arrhythmic adverse event compared to those receiving placebo (9 % vs. 37%, p=0.025) and significantly more patients who received Provacel experienced improvement in their overall condition at six months as compared to those receiving placebo (42% vs. 11%, p=0.027).

Provacel is a preparation of adult stem cells pre-formulated for intravenous delivery by the drug's manufacture, Osiris Therapeutics. Patients were administered an infusion of either Provacel or placebo within 10 days of having a heart attack and are being followed for 2 years. To prevent bias, neither the patient nor the physician knows who received the stem cell treatment and who received placebo.

Rush principal investigator cardiologist Dr. Gary Schaer, head of the Rush Cardiac Catheterization Laboratory, says one reason the study results are so promising is that these stem cells can be used without tissue typing and do not trigger an immune response, and are available for every patient.

The mesenchymal stem cells (MSC) are found in the adult bone marrow and have the potential to develop into mature heart cells and new blood vessels. The MSC cells are derived from normal, healthy adult volunteer bone marrow donors and are not derived from a fetus, embryo or animal. Because they are in an early stage of developm
'"/>

Source:Rush University Medical Center


Page: 1 2

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... Va. , March 12, 2015 IriTech, ... and a member of the Texas Instruments Design Network, ... Naidu has demonstrated its IriShield USB MK2120U device ... scanning facility for pension distribution. The ... assembled to be marketed in India ...
(Date:3/11/2015)... DUBLIN , Mar. 11, 2015 Research and ... addition of the "Access Control Market by Product, ... to 2020" report to their offering. , ... is expected to reach $10.4 billion by 2020, with ... control market report covers the products types such as ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... from the University of California at San Francisco (UCSF) ... dedicated to the brain that the controversy is over: ... dead. , The cerebral cortex is a sheet of ... that process particular aspects of sensation, movement and cognition. ...
... of genes has shed light on the role of gene ... in Proceedings of the National Academy of Sciences USA, was ... , Dr Robert Beiko, Professor Mark Ragan and Mr ... in an effort to map how genes are shared between ...
... used by the U.S. military to track vehicle convoys in ... little-known world of pygmy elephants in Borneo. , ... elephant's being captured and outfitted with a collar that can ... the first time, the public can track the movements of ...
Cached Biology News:MIT researcher presents new view of how the cortex forms 2Lateral thinking produces first map of gene transmission 2WWF peeks into mysterious life of Borneo's pygmy elephants 2
(Date:3/26/2015)... March 26, 2015 ReliantHeart, Inc., an ... Transonic, a supplier of precision transit-time flow measurement solutions, ... greatly improve the efficiency of the HeartAssist5® ... patients to experience greater mobility and peace of mind. ... miniature flow board, will draw 1/6th of the power ...
(Date:3/26/2015)... March 26, 2015 WriteResult, a premier ... researchers from Yale University’s School of Public Health and ... participants during a 4 month-long project. The goal of ... low income families with free access to fresh produce ... diet-related health concerns like high blood pressure, diabetes and ...
(Date:3/25/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... recent discussions with certain shareholders representing approximately 45% of ... dealing with certain matters including the appointment of auditors ... March 26, 2015 (the "Meeting") it intends to adjourn ... take place when the Meeting reconvenes. The Meeting will ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital ... Factual Stock Report coverage on Abattis Bioceuticals ... ATTBF; CSE: ATT): is a specialty biotechnology company ... cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, ... in North America . The ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... BERNARDSVILLE, N.J., March 16 Protocol Driven Healthcare ... its health risk assessment (HRA), the ConXus(R) ... low literacy and reduces processing costs of paper assessments. ... adult HRA, but joins PDHI,s suite of ConXus ...
... Provider, Offers Traceability Down to the Unit Level to Secure ... ... Southborough, MA (PRWEB) March 16, 2009 -- PHARMORX ... technology services provider, today announced the availability of its new ...
... Application Includes Data from a Comparative Trial in ... Inc. announced today that its supplemental New Drug ... Drug Administration (FDA) seeking market approval of Durezol(TM) ... uveitis has been accepted for review. Durezol, ...
Cached Biology Technology:PDHI Launches Short Form of Its ConXus Profile Health Assessment 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 3Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 2Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 3Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 4Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 5
... System brings together two mature, well-understood ... capture surfaces. This combination produces a ... the detection of molecular binding events ... , Protein-specific capture molecules are immobilized ...
... polymers) are prepared by ... the enzyme, polynucleotide phosphorylase, ... the appropriate, ribonucleoside diphosphate ... exception of catalog number ...
... comprehensive experiment based analysis package designed with ... sophisticated and powerful functionality., Image acquisition interface ... for easy image capture. Sequential and ... Playback Saturation Warning ...
...
Biology Products: